EYPT Q3 2017 Earnings — EyePoint Pharmaceuticals, Inc. Revenue & Financial Results | Market Cap Arena

EYPTEyePoint Pharmaceuticals, Inc.

$1B

Q3 2017 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$385,000+39.0% YoY

Gross Profit

$385,000100.0% margin

Operating Income

-$6M-1560.0% margin

Net Income

-$6M-1554.0% margin

EPS (Diluted)

$-1.52

QoQ Revenue Growth

-45.1%

Cash Flow

Operating Cash Flow

-$6M

Free Cash Flow

-$6M

Stock-Based Comp.

$681,000

Balance Sheet

Total Assets

$13M

Total Liabilities

$4M

Stockholders' Equity

$9M

Cash & Equivalents

$12M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$385,000	$277,000	+39.0%
Gross Profit	$385,000	-$3M	+111.1%
Operating Income	-$6M	-$7M	+16.4%
Net Income	-$6M	-$7M	+16.5%